PEN 425 SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

PEN ▼ -0.63% at T+5d

LONG call ✗ call lost -0.63% · α vs SPY -2.14% · entry $324.65 → $322.59

Next anchor: T+20d in 16d

Currently $327.38 · +0.84% from $324.65 entry

Entry anchored
May 7, 04:55 AM ET
via Databento tick

T+1d

-0.75%

call -0.75% · α -1.58%

$322.23

settled 12d ago

T+5d

-0.63%

call -0.63% · α -2.14%

$322.59

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Penumbra shareholders voted overwhelmingly to approve the merger with Boston Scientific, with 99.7% of votes cast in favor. The deal now awaits remaining regulatory clearances (HSR and foreign antitrust) and is expected to close in the second half of 2026.

Actionable Insight

The shareholder vote removes a key condition to closing. Focus now shifts to regulatory approvals, particularly HSR and non-U.S. antitrust clearances. Monitor for updates on these fronts; any delay or condition could affect the timeline. The expected close in H2 2026 remains intact per Boston Scientific's Q1 call.

Key Facts

28,564,786 votes FOR the merger (99.7% of cast votes), 85,334 AGAINST, 15,813 abstentions
28,665,933 shares present or proxy out of 39,324,084 outstanding (72.9% quorum)
Advisory compensation proposal also approved (27,811,605 FOR)
Merger agreement dated January 14, 2026; Penumbra to survive as wholly owned subsidiary of Boston Scientific
Remaining conditions: HSR waiting period expiration/termination and non-U.S. antitrust/foreign investment clearances

Financial Impact

No financial figures disclosed in this filing; deal value and terms are in prior merger agreement filings.

Risk Factors

Failure to obtain remaining regulatory approvals (HSR, foreign antitrust/investment clearances)
Potential for regulatory conditions that could alter deal terms or timeline

Market Snapshot

Exchange

NYSE

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

36% bullish (22 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
425 Filing (Primary)	0001321732-26-000025
Document: 0001321732-26-000025-index-headers.html	0001321732-26-000025
Document: 0001321732-26-000025-index.html	0001321732-26-000025
Document: 0001321732-26-000025.txt	0001321732-26-000025

6 reports for PEN

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PEN — sortable, filterable
	Type				Now
May 7, 2026 13d ago	425 BULLISH ★ 7/10	$324.65 $322.59	▼ −0.63%	▼ −2.14%	$327.38 (+0.84%)
May 6, 2026 14d ago	8-K BEARISH ★ 6/10	$324.65 $322.59	▲ +0.63%	▲ +2.14%	$327.38 (−0.84%)
Apr 29, 2026 21d ago	DEFA14A NEUTRAL ★ 2/10	—	awaiting T+5	—	—
Apr 17, 2026 4w ago	425 NEUTRAL ★ 4/10	$329.71 $327.98	▼ −0.52%	▼ −1.44%	$327.38 (−0.71%)
Apr 1, 2026 7w ago	DEFM14A BULLISH ★ 8/10	$330.36 $329.77	▼ −0.18%	▼ −3.80%	$327.38 (−0.90%)
Feb 25, 2026 12w ago	8-K MIXED ★ 7/10	$338.67 $339.61	▲ +0.28%	▲ +1.38%	$327.38 (−3.33%)

US Market Status

Market Closed — Opens Thu (< 1m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access